Dr. Jonathan Barratt on Sibeprenlimab for IgAN

#KidneyWk #nephrology #iganephropathy #kidneydisease Jonathan Barratt, PhD, is a professor and lead of the renal research group at the University of Leicester. He is lead author of "The Anti-APRIL Antibody Sibeprenlimab Reduced Circulating Immune Complexes in Patients With IgA Nephropathy in the Phase 2 ENVISION Randomized Controlled Trial,” which was presented at ASN Kidney Week 2024. Joel Topf, MD, spoke with Dr. Barratt at Kidney Week about the findings on this anti-APRIL IgAN treatment.